N/A N=213

Using Health-related Quality of Life (HRQL) in Routine Clinical Care

Chronic Obstructive Pulmonary Disease · Pulmonary Fibrosis · Pulmonary Hypertension · Cystic Fibrosis

Bottom Line

View on ClinicalTrials.gov: NCT00457301 ↗

Enrolled (actual)

213

Serious AEs

0.0%

Results posted

Sep 2009

Primary outcome: Primary: Communication Score — 1.14; 1.50; 1.36; 1.75 Mean number of issues discussed — p=0.05

Study Design & Population

Study type: Observational
Phase: N/A
Interventions: HUI score card (Behavioral)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: University of Alberta
Primary completion: Apr 2007

Outcome Measures

Outcome	Result	p-value
PRIMARY Communication Score	1.14; 1.50; 1.36; 1.75	0.05
PRIMARY Management Composite	0.70; 1.20; 2.19; 3.27	0.001 sig
PRIMARY EuroQol, EQ-5D.	0.76; 0.76; 0.75; 0.72	0.46
SECONDARY The Hospital Anxiety and Depression Scale,HADS. Completed at Baseline and End of the Study.	6.41; 5.81; 4.87; 4.31; 5.70; 5.69	0.34

Summary

The objective of this study is to assess the effects of using HRQL measures in the clinical care of pre- and post-lung transplant patients. The hypotheses are that the inclusion of HRQL measures, the Health Utilities Index System Mark 2(HUI2) and Mark 3 (HUI3), in routine clinical care of pre- and post-lung transplant patients, will: 1) improve patient-clinician communication;2) affect patient management; 3) improve patients' HRQL.

Eligibility Criteria

Inclusion Criteria

pre-lung transplant: subjects who are included on the waiting list and are being seen at the out-patient clinic
post-lung transplant subjects.

Exclusion Criteria

younger than 18 years of age
diagnosed as being cognitively impaired
unable to complete questionnaires in English

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00457301). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.